KRAS and neoplasm: In contrast, the 3x-transgenic Kras-activating and p53-inactivating mutant mice develop PDAC at a high rate (97%) and accurately reflect its clinical profile of cachexia, metastases and hemorrhagic ascites, whereby the unrealistic tumor mass or inoculation sites (that are required for other cancer cachexia models) can be avoided.